A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: A pediatric blood and marrow transplant consortium study

Victor M. Aquino, A. R. Harvey, J. H. Garvin, K. T. Godder, M. L. Nieder, R. H. Adams, G. B. Jackson, E. S. Sandler

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2g/ m2/dose (maximum dose 4g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0±0.3 vs 3.9±0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1±1.5 vs 19.3±2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3±1.7 vs 27.3±3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.

Original languageEnglish (US)
Pages (from-to)611-616
Number of pages6
JournalBone Marrow Transplantation
Volume36
Issue number7
DOIs
StatePublished - Oct 2005

Fingerprint

Mucositis
Hematopoietic Stem Cell Transplantation
Glutamine
Bone Marrow
Placebos
Pediatrics
Glycine
Transplants
Total Parenteral Nutrition
Narcotics
Hematopoietic Stem Cells
Patient Care
Morbidity
Drug Therapy

Keywords

  • Glutamine
  • Mucositis
  • Pediatrics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation : A pediatric blood and marrow transplant consortium study. / Aquino, Victor M.; Harvey, A. R.; Garvin, J. H.; Godder, K. T.; Nieder, M. L.; Adams, R. H.; Jackson, G. B.; Sandler, E. S.

In: Bone Marrow Transplantation, Vol. 36, No. 7, 10.2005, p. 611-616.

Research output: Contribution to journalArticle

@article{fec56c3685484b2d9dd2d7f53fd5b0ab,
title = "A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: A pediatric blood and marrow transplant consortium study",
abstract = "Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2g/ m2/dose (maximum dose 4g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0±0.3 vs 3.9±0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1±1.5 vs 19.3±2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3±1.7 vs 27.3±3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.",
keywords = "Glutamine, Mucositis, Pediatrics",
author = "Aquino, {Victor M.} and Harvey, {A. R.} and Garvin, {J. H.} and Godder, {K. T.} and Nieder, {M. L.} and Adams, {R. H.} and Jackson, {G. B.} and Sandler, {E. S.}",
year = "2005",
month = "10",
doi = "10.1038/sj.bmt.1705084",
language = "English (US)",
volume = "36",
pages = "611--616",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation

T2 - A pediatric blood and marrow transplant consortium study

AU - Aquino, Victor M.

AU - Harvey, A. R.

AU - Garvin, J. H.

AU - Godder, K. T.

AU - Nieder, M. L.

AU - Adams, R. H.

AU - Jackson, G. B.

AU - Sandler, E. S.

PY - 2005/10

Y1 - 2005/10

N2 - Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2g/ m2/dose (maximum dose 4g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0±0.3 vs 3.9±0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1±1.5 vs 19.3±2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3±1.7 vs 27.3±3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.

AB - Severe mucositis is a common cause of morbidity in hematopoietic stem cell transplant (HSCT) recipients. Glutamine has been shown to reduce mucositis in children receiving chemotherapy. Patients were randomized in a double-blind manner to receive glutamine or glycine at a dose of 2g/ m2/dose (maximum dose 4g) twice daily until 28 days post transplant or discharge if sooner. Mucositis was graded by use of a modified Walsh scale. A total of 120 children were evaluable: 57 children received glutamine and 63 received glycine. The mean mucositis score was 3.0±0.3 vs 3.9±0.4 (P=0.07) in the glutamine and glycine groups, respectively. The glutamine group demonstrated a reduction in mean number of days of intravenous narcotics use (12.1±1.5 vs 19.3±2.8 in the glycine group, P=0.03) and total parenteral nutrition (17.3±1.7 vs 27.3±3.6 in glycine group, P=0.01). There was no statistically significant difference in toxicity between the two groups. Glutamine appears to be safe and beneficial in reducing the severity of mucositis. Strong consideration should be given to include oral glutamine supplementation as a routine part of supportive care of SCT patients.

KW - Glutamine

KW - Mucositis

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=30944441441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944441441&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705084

DO - 10.1038/sj.bmt.1705084

M3 - Article

C2 - 16086046

AN - SCOPUS:30944441441

VL - 36

SP - 611

EP - 616

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -